BACKGROUND:Survival of patients with early-stage breast cancer is improved following treatment with single-modality tamoxifen, ovarian ablation or suppression, or chemotherapy. The Adjuvant Breast Cancer Trials were designed to ascertain any additional benefits of combined treatment. METHODS: The Adjuvant Breast Cancer Chemotherapy Trial was a randomized phase III trial in which patients with early-stage breast cancer who were receiving prolonged (5 years) tamoxifen treatment, with or without ovarian ablation or suppression, were randomly assigned to standard chemotherapy versus none. Trial endpoints included relapse-free and overall survival. Hazard ratios (HRs) were derived from Cox models, and all statistical tests were two-sided. RESULTS:Between 1992 and 2000, 1991 patients between the ages of 26 and 81 years were randomly assigned (987 to chemotherapy, 1004 to no chemotherapy) from 106 UK and 16 non-UK centers. Nine hundred seven (92%) patients received chemotherapy as allocated (87% received cyclophosphamide, methotrexate, and 5-fluorouracil; 11% received anthracycline-containing regimens). A total of 244 of the 619 premenopausal patients receivedelective ovarian ablation or suppression. Chemotherapy improved relapse-free survival (relapse in the chemotherapy group versus no-chemotherapy group, 298 events versus 332 events, HR = 0.86, 95% confidence interval [CI] = 0.73 to 1.01; P = .06) and overall survival (death from any cause in the chemotherapy group versus no-chemotherapy group, 243 events versus 282 events, HR = 0.83, 95% CI = 0.70 to 0.99; P = .03) after adjustment for nodal status, estrogen receptor status, and age. Subgroup analyses showed that the benefit of chemotherapy was greatest in younger women (<50 years) and in particular for premenopausal women not receiving ovarian ablation or suppression. CONCLUSION: Modest yet sustainable benefits for chemoendocrine therapy occur in women with breast cancer. However, the full impact on overall survival may not emerge for several years.
RCT Entities:
BACKGROUND: Survival of patients with early-stage breast cancer is improved following treatment with single-modality tamoxifen, ovarian ablation or suppression, or chemotherapy. The Adjuvant Breast Cancer Trials were designed to ascertain any additional benefits of combined treatment. METHODS: The Adjuvant Breast Cancer Chemotherapy Trial was a randomized phase III trial in which patients with early-stage breast cancer who were receiving prolonged (5 years) tamoxifen treatment, with or without ovarian ablation or suppression, were randomly assigned to standard chemotherapy versus none. Trial endpoints included relapse-free and overall survival. Hazard ratios (HRs) were derived from Cox models, and all statistical tests were two-sided. RESULTS: Between 1992 and 2000, 1991 patients between the ages of 26 and 81 years were randomly assigned (987 to chemotherapy, 1004 to no chemotherapy) from 106 UK and 16 non-UK centers. Nine hundred seven (92%) patients received chemotherapy as allocated (87% received cyclophosphamide, methotrexate, and 5-fluorouracil; 11% received anthracycline-containing regimens). A total of 244 of the 619 premenopausal patients received elective ovarian ablation or suppression. Chemotherapy improved relapse-free survival (relapse in the chemotherapy group versus no-chemotherapy group, 298 events versus 332 events, HR = 0.86, 95% confidence interval [CI] = 0.73 to 1.01; P = .06) and overall survival (death from any cause in the chemotherapy group versus no-chemotherapy group, 243 events versus 282 events, HR = 0.83, 95% CI = 0.70 to 0.99; P = .03) after adjustment for nodal status, estrogen receptor status, and age. Subgroup analyses showed that the benefit of chemotherapy was greatest in younger women (<50 years) and in particular for premenopausal women not receiving ovarian ablation or suppression. CONCLUSION: Modest yet sustainable benefits for chemoendocrine therapy occur in women with breast cancer. However, the full impact on overall survival may not emerge for several years.
Authors: Fabrice Andre; Kristine Broglio; Lajos Pusztai; Narjiss Berrada; John R Mackey; Jean Marc Nabholtz; Stephen Chan; Gabriel N Hortobagyi Journal: Oncologist Date: 2010-04-26
Authors: Benjamin D Hedley; Kedar S Vaidya; Pushar Phadke; Lisa MacKenzie; David W Dales; Carl O Postenka; Ian C MacDonald; Ann F Chambers Journal: Clin Exp Metastasis Date: 2008-06-10 Impact factor: 5.150
Authors: Isabel Pinhel; Margaret Hills; Suzanne Drury; Janine Salter; Georges Sumo; Roger A'Hern; Judith M Bliss; Ivana Sestak; Jack Cuzick; Peter Barrett-Lee; Adrian Harris; Mitch Dowsett Journal: Breast Cancer Res Date: 2012-03-14 Impact factor: 6.466
Authors: Sirwan M Hadad; Lee Baker; Philip R Quinlan; Katherine E Robertson; Susan E Bray; George Thomson; David Kellock; Lee B Jordan; Colin A Purdie; David G Hardie; Stewart Fleming; Alastair M Thompson Journal: BMC Cancer Date: 2009-09-01 Impact factor: 4.430
Authors: M Loddo; S R Kingsbury; M Rashid; I Proctor; C Holt; J Young; S El-Sheikh; M Falzon; K L Eward; T Prevost; R Sainsbury; K Stoeber; G H Williams Journal: Br J Cancer Date: 2009-02-24 Impact factor: 7.640
Authors: Anna V Britto; André A Schenka; Natália G Moraes-Schenka; Marcelo Alvarenga; Júlia Y Shinzato; José Vassallo; Laura S Ward Journal: BMC Cancer Date: 2009-04-08 Impact factor: 4.430